Although a 6 log kill, associated with chemotherapy, may produce volume reduction and increase mean survival, it can sterilize only very small tumor burdens. The problems of low log kill associated with chemotherapy are highlighted by studies of pre-transplantation TACE which demonstrate that complete histological tumor necrosis is rarely achieved.33 The poor tumor sterilization of HCC with chemotherapy is to be expected given the complex microvasculature of hepatic tumors which restricts chemotherapy or ablation effects on many clonogens. Radiotherapy may also offer significant advantages over liver resection

and RFA as it can be delivered to liver lesions in all sites, and its use is not contraindicated by the proximity of lesions to major vessels or bile ducts. These structures, if intact, are relatively tolerant to irradiation, and adjacent tumors can be irradiated http://www.selleckchem.com/products/ganetespib-sta-9090.html without undue concern about subsequent vascular or biliary injury. The non-invasive nature of radiotherapy also removes the risk of tumor seeding associated with percutaneous ablation of high-risk lesions. Finally, the non-invasive, outpatient nature of external beam radiotherapy GSK-3 inhibition may be cheaper and easier for patients

compared with invasive treatment requiring inpatient admission. Conventional radiotherapy is a relatively cheap means of treatment. Given as an outpatient, the costs in Australia may be derived using the Commonwealth Governments Schedule of Fees which are based primarily on the complexity of treatments and number of treatments. When specialist consultation fees, simulation and planning fees and treatment with 30 fractions using

a three-field technique are included, the costs per course of treatment are approximately $A 4047. The costs are less if fewer fractions are used. Other estimates for courses of treatment are $A 2545,34 $CA 2583,35 $CA 396936 and £1260.37 Using larger, fewer fractions is an option but at this stage it is safer to use conventional fractions of approximately MCE公司 2.0 Gy per fraction where most clinical experience of HCC has been gained. In conclusion, further clinical trials are required to provide a firmer clinical evidence base for radiotherapy of HCC. In our view, there is a clear need for high-quality trials comparing radiotherapy (alone and combined) with current standards of care for early-stage HCC not eligible for surgical therapies, intermediate stage and advanced-stage HCC. Further research to define tumor and normal tissue parameters for radiobiology modeling is particularly important. Radiotherapy is not a new therapy and is therefore unlikely to be as vigorously promoted as newer treatment alternatives. However, the worldwide importance of HCC and the limitations of current therapies suggest the need for new approaches to this cancer.